These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33650732)

  • 21. [Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].
    Fan LK; Wang ZW; Hua BL; Su W; Wang SJ; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):551-4. PubMed ID: 19968068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation.
    Meijer P; Verbruggen B
    Semin Thromb Hemost; 2009 Nov; 35(8):786-93. PubMed ID: 20169515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
    Field JJ; Fenske TS; Blinder MA
    Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.
    Türkantoz H; Königs C; Knöbl P; Klamroth R; Holstein K; Huth-Kühne A; Heinz J; Eichler H; Tiede A
    J Thromb Haemost; 2020 Jan; 18(1):36-43. PubMed ID: 31448877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors.
    Favaloro EJ; Bonar R; Kershaw G; Duncan E; Sioufi J; Marsden K
    Semin Thromb Hemost; 2009 Nov; 35(8):794-805. PubMed ID: 20169516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay.
    Kim SY; Kang SY; Lee WI
    Korean J Lab Med; 2010 Jun; 30(3):260-3. PubMed ID: 20603586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
    Verbruggen B; van Heerde WL; Laros-van Gorkom BA
    Semin Thromb Hemost; 2009 Nov; 35(8):752-9. PubMed ID: 20169511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. External quality assessment of factor VIII inhibitor assays.
    Bonar RA; Favaloro EJ; Marsden K
    Semin Thromb Hemost; 2013 Apr; 39(3):320-6. PubMed ID: 23436565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.
    Miller CH; Platt SJ; Rice AS; Kelly F; Soucie JM;
    J Thromb Haemost; 2012 Jun; 10(6):1055-61. PubMed ID: 22435927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients.
    Rampersad AG; Boylan B; Miller CH; Shapiro A
    Haemophilia; 2018 Sep; 24(5):807-814. PubMed ID: 30004159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.
    Leissinger C; Josephson CD; Granger S; Konkle BA; Kruse-Jarres R; Ragni MV; Journeycake JM; Valentino L; Key NS; Gill JC; McCrae KR; Neufeld EJ; Manno C; Raffini L; Saxena K; Torres M; Marder V; Bennett CM; Assmann SF
    Thromb Haemost; 2014 Sep; 112(3):445-58. PubMed ID: 24919980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor.
    Croteau SE; Abajas YL; Wolberg AS; Nielsen BI; Marx GR; Baird CW; Neufeld EJ; Monahan PE
    Haemophilia; 2017 Mar; 23(2):e93-e98. PubMed ID: 28124406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
    Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP
    Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects.
    Favaloro EJ; Gilmore G; Bonar R; Dean E; Arunachalam S; Mohammed S; Baker R
    Haemophilia; 2020 Mar; 26(2):354-362. PubMed ID: 31962376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance evaluation of Revohem
    Suzuki A; Suzuki N; Kanematsu T; Shinohara S; Arai N; Kikuchi R; Matsushita T
    Int J Lab Hematol; 2019 Oct; 41(5):664-670. PubMed ID: 31271527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Screening and analysis of coagulation factor VIII inhibitor in patients with hemophilia A].
    Zhang AL; Yang LH; Liu XE; Zhao H; Zhang JH; Dong CX; Qi XL; Qin XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):968-70. PubMed ID: 21867625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.
    Sahud MA; Pratt KP; Zhukov O; Qu K; Thompson AR
    Haemophilia; 2007 May; 13(3):317-22. PubMed ID: 17498082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.
    Mancuso ME; Fischer K; Santagostino E; Oldenburg J; Platokouki H; Königs C; Escuriola-Ettingshausen C; Rivard GE; Cid AR; Carcao M; Ljung R; Petrini P; Altisent C; Kenet G; Liesner R; Kurnik K; Auerswald G; Chambost H; Mäkipernaa A; Molinari AC; Williams M; van den Berg HM;
    Thromb Haemost; 2017 Dec; 117(12):2274-2282. PubMed ID: 29212115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
    Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
    Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
    Amiral J; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.